Artigos de revistas sobre o tema "Initiation et transformation leucémique"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Initiation et transformation leucémique".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Vénal, L., E. Liozon, C. Brigaudeau, T. Papo, F. Chariotte, P. Soria, V. Loustaud e E. Vidal. "Syndromes hyperéosinophiliques de présentation classique avec évolution clonale et transformation leucémique". La Revue de Médecine Interne 19 (junho de 1998): 118S. http://dx.doi.org/10.1016/s0248-8663(98)80187-2.
Texto completo da fonteCardin, Lise, Daphné Bolz e Jean Saint-Martin. "Nelson Paillou et la transformation du handball en France (1942–1982) : Entre discours et réalités". STADION 44, n.º 2 (2020): 366–89. http://dx.doi.org/10.5771/0172-4029-2020-2-366.
Texto completo da fonteDeschênes-Simard, Xavier, Yusuke Mizukami e Nabeel Bardeesy. "Macrophages in pancreatic cancer: Starting things off on the wrong track". Journal of Cell Biology 202, n.º 3 (5 de agosto de 2013): 403–5. http://dx.doi.org/10.1083/jcb.201307066.
Texto completo da fonteHassan, L. "Successful genetic transformation in date palm (Phoenix dactylifera)". Journal of the Bangladesh Agricultural University 11, n.º 2 (4 de agosto de 2014): 171–76. http://dx.doi.org/10.3329/jbau.v11i2.19841.
Texto completo da fonteCai, Xiongwei, Yoshihiro Hayashi, Mark Wunderlich, Nancy A. Speck, James C. Mulloy, Gang Huang e Yi Zheng. "Loss of Function RUNX1 Mutations Restrict Protein Biosynthesis during Pre-Leukemia and MDS Transition but Not after Leukemic Transformation". Blood 128, n.º 22 (2 de dezembro de 2016): 3860. http://dx.doi.org/10.1182/blood.v128.22.3860.3860.
Texto completo da fonteHurtz, Christian, Huimin Geng, Gang Xiao, Mignon L. Loh, B. Hilda Ye, Ari Melnick e Markus Muschen. "BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia". Blood 124, n.º 21 (6 de dezembro de 2014): 3570. http://dx.doi.org/10.1182/blood.v124.21.3570.3570.
Texto completo da fonteAivalioti, Maria M., Tushar D. Bhagat, Aditi Paranjpe, Boris Bartholdy, Kith Pradhan, Mario Pujato, Amit Verma e Britta Will. "PU.1-Dependent Enhancer Decommissioning Drives Transformation of Tet2 deficient Hematopoietic Stem and Progenitor Cells". Blood 136, Supplement 1 (5 de novembro de 2020): 40. http://dx.doi.org/10.1182/blood-2020-142070.
Texto completo da fonteGouzi, Fares, François Bughin, Lucie Barateau, Agathe Hubert, Savine Volland, Dalila Laoudj-Chenivesse, Emilie Passerieux et al. "Utilisation d’outils numériques dans le cadre d’un dispositif hybride pour l’apprentissage par problème de la physiologie en deuxième année des études médicales. Étude de faisabilité du recours au laboratoire numérique de physiologie « e-ϕsioLab »." Pédagogie Médicale 19, n.º 2 (2018): 77–90. http://dx.doi.org/10.1051/pmed/2019007.
Texto completo da fonteYan, Dongqing, e Golam Mohi. "Critical Role for Stat5 in the Initiation and Maintenance of Polycythemia Vera in a Jak2V617F Knock-In Mouse Model". Blood 118, n.º 21 (18 de novembro de 2011): 121. http://dx.doi.org/10.1182/blood.v118.21.121.121.
Texto completo da fonteArora, Sankalp, Jayastu Senapati, Naveen Pemmaraju, Prithviraj Bose, Lucia Masarova, Guillermo Montalban-Bravo, Abhishek Maiti et al. "Five-Year Follow up Results of Phase II Clinical Trial Evaluating Ruxolitinib (RUX) and Azacitidine (AZA) Combination Therapy in Patients (pts) with Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)". Blood 142, Supplement 1 (28 de novembro de 2023): 1861. http://dx.doi.org/10.1182/blood-2023-187035.
Texto completo da fonteHurtz, Christian, Lai N. Chan, Erica Ballabio, Cheryl L. Willman, William L. Carroll, Scott A. Armstrong, Patricia Ernst, Ari Melnick, Thomas Milne e Markus Müschen. "Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia". Blood 128, n.º 22 (2 de dezembro de 2016): 907. http://dx.doi.org/10.1182/blood.v128.22.907.907.
Texto completo da fonteOzpolat, Bulent, Ugur Akar, Magaly Barria e Gabriel Lopez-Berestein. "PKCδ Regulates Eukaryotic Initiation Factor eIF2α through PKR during Retinoic Acid-Induced Myeloid Cell Differentiation." Blood 108, n.º 11 (16 de novembro de 2006): 1928. http://dx.doi.org/10.1182/blood.v108.11.1928.1928.
Texto completo da fonteMinami, Yosuke, Scott A. Stuart, Tomokatsu Ikawa, Akihiro Abe, Tomoki Naoe, Catriona H. M. Jamieson e Jean Y. J. Wang. "Transformation of E2A-Deficient Pluripotent Progenitors by BCR-ABL Generates Imatinib-Resistant Leukemic Stem Cells." Blood 112, n.º 11 (16 de novembro de 2008): 1342. http://dx.doi.org/10.1182/blood.v112.11.1342.1342.
Texto completo da fonteChan, Lai N., Christian Hurtz, Gang Xiao, Seyedmehdi Shojaee, Rebecca Caeser, Huimin Geng, Ari Melnick e Markus Müschen. "BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation". Blood 128, n.º 22 (2 de dezembro de 2016): 438. http://dx.doi.org/10.1182/blood.v128.22.438.438.
Texto completo da fonteLee, Christine Shu Mei, Kristen L. Estabrooks, Kaitao Lai, Agnibesh Dey, Jonathan Cheng, Shane Whittaker, Chuen Wen Tan et al. "Procoagulant Platelet Subpopulation As a Novel Predictive Biomarker of Poor Outcomes in Essential Thrombocythemia". Blood 138, Supplement 1 (5 de novembro de 2021): 3622. http://dx.doi.org/10.1182/blood-2021-152075.
Texto completo da fonteLi, Qiang, Christian Hurtz, Seyedmehdi Shojaee, Zhengshan Chen, Huimin Geng, Gang Xiao, Mignon L. Loh, B. Hilda Ye, Ari Melnick e Markus Muschen. "Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia". Blood 126, n.º 23 (3 de dezembro de 2015): 556. http://dx.doi.org/10.1182/blood.v126.23.556.556.
Texto completo da fonteMaura, Francesco, Even H. Rustad, Niccolò Bolli, Venkata Yellapantula, Daniel A. Leongamornlert, Ferran Nadeu, Nicos Angelopoulos et al. "Timing the Initiation of Multiple Myeloma". Blood 134, Supplement_1 (13 de novembro de 2019): 573. http://dx.doi.org/10.1182/blood-2019-124357.
Texto completo da fonteRopa, James, Nirmalya SAHA e Andrew G. Muntean. "SETDB1 Represses Hox Gene Expression and Suppresses Acute Myeloid Leukemia". Blood 132, Supplement 1 (29 de novembro de 2018): 1320. http://dx.doi.org/10.1182/blood-2018-99-117690.
Texto completo da fonteChan, Lai N., Christian Hurtz, Etienne Leveille, Kohei Kume, Mark E. Robinson, Huimin Geng, Kadriye Nehir Cosgun e Markus Müschen. "Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation". Blood 138, Supplement 1 (5 de novembro de 2021): 792. http://dx.doi.org/10.1182/blood-2021-148653.
Texto completo da fonteFreeman, Ciara Louise, Kerry J. Savage, Diego Villa, David W. Scott, Alina S. Gerrie, David J. Ferguson, Fergus Cafferty et al. "Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma". Blood 132, Supplement 1 (29 de novembro de 2018): 2873. http://dx.doi.org/10.1182/blood-2018-99-113675.
Texto completo da fonteBojko, Peter, Wolfgang Abenhardt, Susanne Schnittger e Torsten Haferlach. "Analysis of the V617F Mutation of the JAK2- and the W515 Mutation of the MPL Gene in Patients with Chronic Myeloproliferative Disease (CMPD) Treated in an Outpatient Practice." Blood 110, n.º 11 (16 de novembro de 2007): 4631. http://dx.doi.org/10.1182/blood.v110.11.4631.4631.
Texto completo da fonteFruehwirth, Margareta, Alexander J. A. Deutsch, Philipp B. Staber, Ariane Aigelsreiter, Werner Linkesch, Christine Beham-Schmid e Peter Neumeister. "Aberrant Somatic Hypermutation of Follicular Lymphoma Transformed To Diffuse Large B-Cell Lymphoma." Blood 108, n.º 11 (1 de novembro de 2006): 2413. http://dx.doi.org/10.1182/blood.v108.11.2413.2413.
Texto completo da fonteGupta, Shikha, Ana Filipa Domingues, Oliwia Cyran, George Giotopoulos, Sudhakaran Prabakaran, Brian J. P. Huntly, Oliver M. Dovey, George S. Vassiliou e Cristina Pina. "Transcriptional Heterogeneity Governs Cell Fate Diversification during Pre-Leukemia to Leukemia Progression". Blood 136, Supplement 1 (5 de novembro de 2020): 31–32. http://dx.doi.org/10.1182/blood-2020-136504.
Texto completo da fonteNaqvi, Syed Arsalan Ahmed, Irbaz Bin Riaz, Manal Imran, Muhammad Daim Bin Zafar, Kunwer Sufyan Faisal, Zaryab Bin Riaz, Parminder Singh e Alan Haruo Bryce. "Deep prostate-specific antigen response and overall survival in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis." Journal of Clinical Oncology 41, n.º 6_suppl (20 de fevereiro de 2023): 195. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.195.
Texto completo da fonteJeannet, Robin, Qi Cai, Hongjun Liu, Hieu Vu e Ya-Huei Kuo. "Alcam Mediated Interaction Regulates Normal Hematopoietic Stem Cell Function and Cbfβ-SMMHC Induced Leukemogenesis". Blood 120, n.º 21 (16 de novembro de 2012): 4091. http://dx.doi.org/10.1182/blood.v120.21.4091.4091.
Texto completo da fonteLaffey, Kimberly G., Robert J. Stiles, Melissa Ludescher, Tessa Davis, Shariq S. Khwaja, Richard J. Bram, Peter J. Wettstein et al. "A New Mechanism for T-ALL Leukemogenesis: Early Expression of Alpha-Beta TCR Occurs in a Natural Subset of CD4-CD8- Double Negative (DN) Thymocytes Where MHC Engagement May Drive NOTCH Mutation and Tumor Initiation". Blood 134, Supplement_1 (13 de novembro de 2019): 1463. http://dx.doi.org/10.1182/blood-2019-131897.
Texto completo da fonteQuere, Ronan, Göran Karlsson, Falk Hertwig, Marianne Rissler, Beata Lindqvist, Thoas Fioretos, Peter Vandenberghe et al. "SMAD4 Sequestrates HOXA9 to Protect Hematopoietic Stem Cells Against Leukemia Transformation". Blood 116, n.º 21 (19 de novembro de 2010): 3153. http://dx.doi.org/10.1182/blood.v116.21.3153.3153.
Texto completo da fonteLinton, Kim, Cristina Julian, Adam Gibb, Ellie White, Emma-Frances Armstrong, Yun Li, Yutong Liu, Ashwini Shewade e John Radford. "Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Who Received Third Line Therapy at the Christie NHS Foundation Trust in the UK". Blood 138, Supplement 1 (5 de novembro de 2021): 5011. http://dx.doi.org/10.1182/blood-2021-148490.
Texto completo da fonteKingsley, Edwin C., Shannon Fabre, Motohisa Takai, Aileen Cleary Cohen, Jingjing Schneider, Jessica Li e James D'Olimpio. "A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor (BTKi) Zanubrutinib in Patients with Waldenström Macroglobulinemia (WM)". Blood 142, Supplement 1 (28 de novembro de 2023): 6171. http://dx.doi.org/10.1182/blood-2023-172881.
Texto completo da fonteHurtz, Christian, Katerina Hatzi, Leandro Cerchietti, Eugene Park, Yong-Mi Kim, Parham Ramezani-Rad, Hassan Jumaa et al. "BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia". Blood 118, n.º 21 (18 de novembro de 2011): 446. http://dx.doi.org/10.1182/blood.v118.21.446.446.
Texto completo da fonteLudvigsen Al-Mashhadi, Ahmed, Mikkel Runason Runason Simonsen, Chan Yoon Cheah, Rose-Marie Amini, Bente Arboe, James R. Cerhan, Iman Chanchiri et al. "Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up". Blood 142, Supplement 1 (28 de novembro de 2023): 4396. http://dx.doi.org/10.1182/blood-2023-173247.
Texto completo da fonteHaaga, John, Hilary Coller, Hung-Ying Kao e Richard T. Lee. "Conversion of nontumorigenic dormant MOLT3 by lactate into a glycolytic cancer via epigenetic changes and lymphangiognesis." Journal of Clinical Oncology 35, n.º 15_suppl (20 de maio de 2017): e23176-e23176. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e23176.
Texto completo da fonteMossner, Maximilian, Johann-Christoph Jann, Evi Lauinger-Lörsch, Daniel Nowak, Uwe Platzbecker, Aristoteles Giagounidis, Katharina S. Götze et al. "TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial". Blood 122, n.º 21 (15 de novembro de 2013): 2759. http://dx.doi.org/10.1182/blood.v122.21.2759.2759.
Texto completo da fonteAkar, Ugur, Bulent Ozpolat, Nancy Colburn e Gabriel Lopez-Berestein. "p38 MAPK Signaling Mediates Retinoic Acid-Induced Expression of a Novel Tumor Suppressor Protein Programmed Cell Death 4 (PDCD4) in Acute Promyelocytic Leukemia Cells." Blood 108, n.º 11 (16 de novembro de 2006): 1942. http://dx.doi.org/10.1182/blood.v108.11.1942.1942.
Texto completo da fonteKomrokji, Rami S., Najla H. Al Ali, Eric Padron, Jeffrey E. Lancet e Alan F. List. "Azacitidine Treatment of Lenalidomide-Resistant Myelodysplastic Syndrome with Deletion 5q". Blood 118, n.º 21 (18 de novembro de 2011): 2774. http://dx.doi.org/10.1182/blood.v118.21.2774.2774.
Texto completo da fonteLin, Kevin H., Lynn Huynh, Xiaoqin Yang, Enrico Zanardo, Lisa Matay, Megan Pinaire, Daria Liborski et al. "Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i)". Blood 142, Supplement 1 (28 de novembro de 2023): 1910. http://dx.doi.org/10.1182/blood-2023-182188.
Texto completo da fonteMohamed-Hadley, Alisha A., Dan A. Liebermann e Barbara Hoffman. "Stress Response Gadd45a Gene as Tumor Suppressor in MYC Expressing Myeloid Cells Is Cytokine Specific." Blood 114, n.º 22 (20 de novembro de 2009): 1481. http://dx.doi.org/10.1182/blood.v114.22.1481.1481.
Texto completo da fonteMcKay, John, Matthew Gayhart, Taha Al-Juhaishi, Victor Yazbeck e Edward B. Perkins. "Venetoclax and Cytarabine in AML Transformed from Myelofibrosis". Blood 134, Supplement_1 (13 de novembro de 2019): 5140. http://dx.doi.org/10.1182/blood-2019-129429.
Texto completo da fonteOzpolat, Bulent, Ugur Akar, Nancy H. Colburn e Gabriel Lopez-Berestein. "Novel Tumor Suppressor Protein Programmed Cell Death 4 (PDCD4) Suppresses Activity of PI3K/Akt Pathway and Regulates Expression of p27 (Kip1) and c-myc, DAP5 and Willm’s Tumor (WT1) in Acute Myeloid Leukemia." Blood 110, n.º 11 (16 de novembro de 2007): 2656. http://dx.doi.org/10.1182/blood.v110.11.2656.2656.
Texto completo da fonteOzpolat, Bulent, Maribel Tirado-Gomez, Nancy H. Colburn e Gabriel Lopez-Berestein. "All-trans-Retinoic acid (ATRA) and Arsenic Trioxide-Induced Expression and Regulation of Programmed Cell Death 4 (PDCD4) in Acute Promyelocytic Leukemia." Blood 104, n.º 11 (16 de novembro de 2004): 886. http://dx.doi.org/10.1182/blood.v104.11.886.886.
Texto completo da fonteChiu, Vi Kien, Rama Gallupalli, Diaa Osman, Zhaoshi Zeng, Jinru Shia, Philip Paty e Anne-France Le Rolle. "Effect of tumor progression on colon cancer stem cell plasticity." Journal of Clinical Oncology 36, n.º 4_suppl (1 de fevereiro de 2018): 688. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.688.
Texto completo da fonteWang, Peng, James C. McWilliams e Claire Ménesguen. "Ageostrophic instability in rotating, stratified interior vertical shear flows". Journal of Fluid Mechanics 755 (19 de agosto de 2014): 397–428. http://dx.doi.org/10.1017/jfm.2014.426.
Texto completo da fonteBatlevi, Connie, Anna Alperovich, Katy Smith, Zhitao Ying, Jacob D. Soumerai, Amanda R. Copeland, Erel Joffe et al. "Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era". Blood 128, n.º 22 (2 de dezembro de 2016): 4119. http://dx.doi.org/10.1182/blood.v128.22.4119.4119.
Texto completo da fonteBrown, Jennifer R., Matthew S. Davids, Julie E. Chang, Shuo Ma, Juliana M. L. Biondo, Yong Mun, Madlaina Breuleux e William G. Wierda. "Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)". Blood 134, Supplement_1 (13 de novembro de 2019): 4320. http://dx.doi.org/10.1182/blood-2019-123665.
Texto completo da fonteMendoza-Castrejon, Jonny, Emily B. Casey, Riddhi M. Patel e Jeffrey A. Magee. "SKIDA1 Sustains MLL-ENL-Expressing Hematopoietic Stem and Progenitor Cells". Blood 138, Supplement 1 (5 de novembro de 2021): 3294. http://dx.doi.org/10.1182/blood-2021-148604.
Texto completo da fonteYsebaert, Loic, Anne-Sophie Michallet, Fontanet Bijou, Aline Clavert, Anne Quinquenel, Anne Calleja, Romain Guieze, Emmanuelle Ferrant, Annie Brion e Kamel Laribi. "Real-World Ibrutinib Validation of the Ball Score to Predict Overall Survival: A Filo Group Study in RR CLL Patients". Blood 134, Supplement_1 (13 de novembro de 2019): 1741. http://dx.doi.org/10.1182/blood-2019-122318.
Texto completo da fontePerez, Ruben Hernandez, Ang Li, Sarvari Venkata Yellapragada, Matthew Zheng, Maria Otazo, Martha Mims e Gustavo A. Rivero. "Intrinsic Biological Variability In High-Risk-Myelodysplastic Syndrome Impacts Overall Survival (OS) In Patients Experiencing Cytogenetic Evolution Treated With Azanucleosides". Blood 122, n.º 21 (15 de novembro de 2013): 1537. http://dx.doi.org/10.1182/blood.v122.21.1537.1537.
Texto completo da fonteKnox, Jennifer J., Mairead Geraldine McNamara, Lipika Goyal, Mark Doherty, Christoph Springfeld, Joon Oh Park, Aimery De Gramont et al. "NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)." Journal of Clinical Oncology 38, n.º 4_suppl (1 de fevereiro de 2020): TPS602. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.tps602.
Texto completo da fonteKnox, Jennifer J., Mairead Geraldine McNamara, Daniel H. Palmer, T. R. Jeffry Evans, David Goldstein, John A. Bridgewater e Juan W. Valle. "NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer." Journal of Clinical Oncology 37, n.º 15_suppl (20 de maio de 2019): TPS4156. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps4156.
Texto completo da fonteChan, Lai N., Christian Hurtz, Huimin Geng, Erica Ballabio, Gang Xiao, Gauri Deb, Haytham Khoury et al. "Rationale for Targeting BCL6 in MLL-Rearranged B-ALL". Blood 134, Supplement_1 (13 de novembro de 2019): 1239. http://dx.doi.org/10.1182/blood-2019-131565.
Texto completo da fonte